ArticleiMetaOmics2025
Gut microbiota and OMVs: Unveiling novel regulatory mechanisms in high-altitude myocardial injury.
Article in iMetaOmics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microbiome and aging: Trajectories of microbiome age across human ecosystems and their systemic effects.iMeta · 2026Review
- Effects of High-Altitude Environments on Gut Microbiota and Their Mechanisms in Immune Regulation and High-Altitude Adaptation.International journal of molecular sciences · 2026Review
- Bacterial outer membrane vesicles as intrinsically immunogenic and highly modifiable nanocarriers for precision tumor therapy.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota influences host health, with outer membrane vesicles (OMVs) facilitating intercellular communication and transporting bioactive molecules. At high altitudes, OMVs can cross the intestinal barrier, affecting heart function and potentially modulating inflammation, oxidative stress, and apoptosis in cardiomyocytes. Genetic engineering of OMVs may improve their therapeutic efficacy by altering surface properties to enhance targeting and residence time. They could also act as disease biomarker carriers for early detection and monitoring.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.